This smartwatch health metric can help you better manage stress
You can find that number on most smartwatches or other wearables right now, but if you glance at yours, it's likely to change before your eyes.
That number is your heart rate variability, or HRV, a measure of your autonomic nervous system's resilience. It's one of the most potentially beneficial health metrics available to us. But it's also widely misunderstood. Many of us haven't a clue what our HRV reading means or how to use it.
Which is too bad, experts say, because research suggests HRV could predict mortality as we get older and help us bring our stress reactions under better control, whatever our age.
'HRV is very useful,' said Andy Galpin, executive director of the Human Performance Center at Parker University in Dallas and a high-performance coach. 'There's a reason it's on every wearable.'
The question is, is your HRV in good shape? And how can you make it better?
Heart rate variability isn't about your heart, or not much. It's 'a proxy of stress,' said Marco Altini, a researcher and the founder of HRV4training, which provides endurance coaching.
Technically, it's the millisecond-by-millisecond change in the intervals between heart beats. If your heart rate right now is 90 beats per minute, those 90 beats aren't spaced consistently. They're syncopated, coming faster and slower every millisecond, depending on, well, 'just about everything,' Altini said.
That's because HRV is 'a reflection' of our autonomic nervous system, he said. The autonomic nervous system controls involuntary processes like breathing and heart rate and is made up of the twitchy sympathetic nervous system, which causes high-alert, fight-or-flight reactions, and the parasympathetic nervous system — our inner Matthew McConaughey, which drawls at us to chill.
Both systems work with the brain to increase or lower heart rate and breathing and to coordinate the release of stress-related biochemicals but typically in opposite directions.
Ideally, these dueling systems interact and balance to keep our bodies ready to react but not overreact to every stress — including hunger, fatigue, worry, illness and exercise — but also cold, politics, deadlines, a car backfiring or almost anything else happening within and around us.
Heart rate variability 'shows where you are in balance between parasympathetic and sympathetic drive,' Galpin said. Generally, a 'higher HRV is better.'
How much better? In a small study of centenarians — men and women who lived to be at least 100 — the higher their HRV, the longer they continued to live. Those with the lowest HRVs were far more likely to die in the coming year than the others.
'HRV seems to play a role in exceptional longevity,' the study's authors concluded.
In general, a higher HRV indicates a healthier stress response, with more input from the parasympathetic than sympathetic systems, said Jay Wiles, a clinical psychologist who uses HRV to help professional athletes and others with stress. A higher HRV suggests that your body is calm but alert, like a boxer bouncing from foot to foot. You're ready to roll with whatever the world throws at you.
But is your current HRV high enough? That question is surprisingly hard to answer.
Most wearables track HRV by measuring your heartbeat intervals in milliseconds, calculating differences from one beat to the next with a proprietary algorithm and graphing changes in your HRV over an hour, day, week, month or whatever. It then provides an average in milliseconds, such as 20, 50, 110 or some other.
That average changes frequently as your nervous system reacts to the world, but it usually stays within a somewhat narrow band, which would be your typical HRV.
Your usual HRV can be quite different from mine, though. In fact, the range of everyday HRVs can be staggeringly large, Altini said. In the most comprehensive study yet of HRVs, people of all ages had average HRVs ranging from as low as 5 milliseconds among some people in their 60s to as much as 230 for some teenagers. Generally, HRV declines with age, but some of the oldest people in the study had HRVs above 80, while some teenagers had HRVs of about 10.
The average for people in their 30s was about 45 milliseconds, but the range for that age group was anywhere from 10 to more than 160 milliseconds.
Many people believe an HRV in the 20s or lower is cause for concern, Altini said. He disagrees.
'There's a strong genetic component,' he said. You may be born with a relatively low HRV, which is normal for you.
How can you know? The best way to find your unique HRV range is with several months' worth of data from your smartwatch or other wearable, Altini said. It's best to use a long period of time because HRVs spike and drop precipitously during a single day, he said. A sudden loud noise might send it spiraling by 100 milliseconds before dropping back to your normal. So, knowing your average range over months gives you a baseline or benchmark of your typical HRV.
You can then use that information to track what's up inside your body, Galpin said. If your typical HRV abruptly drops by a large and lingering amount, at least 10 or 20 milliseconds for at least three to five days, that often signals that something is wrong. 'Your body's freaking out,' Galpin said. Maybe you're getting sick or, if you're an athlete, overtraining, or you might be facing unusual strains at work. At any rate, a substantial, prolonged HRV decline is 'worth paying attention to,' Galpin said.
What can or should you do about a tumbling HRV?
'The goal isn't to fix your HRV,' Wiles said. The goal is to fix — or, at least, find and face — whatever is damping your HRV. Are you training for a marathon? Maybe lower your mileage for a day or two. Or check your temperature to determine whether you're getting sick.
You can also work on becoming better able to handle stress in general. Meditation and slow, deliberate breathing tend to activate the parasympathetic nervous system, Wiles said, which will usually result in heightened HRV, both immediately and long-term.
He also uses biofeedback with his clients, many of whom are professional athletes, to strengthen their stress resilience and, at the same time, raise their HRV. Prompted by an app on their phone or another screen, they breathe slowly and deeply, with about five seconds of inhaling and five seconds of exhaling, while watching a graph of their HRV. It should slowly rise.
This practice can help athletes and the rest of us learn to reach a state of flow, Wiles said, of calm responsiveness even under stress. (If you want to try HRV-related biofeedback at home, he recommends the app HRV4Biofeedback, which was developed by Altini. It costs about $10 and requires only a cellphone, not a smartwatch, to measure HRV.)
Even more important is to look at your entire life, Galpin said. If you're not exercising, eating well and sleeping enough or if you smoke or drink heavily, your HRV will be lower than it should be.
'Remove those big health anchors,' he said, and your HRV will rise, as will your overall quality of life, which is, of course, the primary goal. HRV just marks your journey there, he said. 'It's the metric you watch to make sure your whole health program is actually working.'
Do you have a fitness question? Email YourMove@washpost.com and we may answer your question in a future column.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


WebMD
7 minutes ago
- WebMD
The Surge in Type 1 Diabetes, and the New Ways to Fight It
Aug. 19, 2025 — Cases of type 1 diabetes — an autoimmune condition where the body attacks insulin-producing beta cells — are rising faster than ever, climbing about 42% in since 1990. That's a huge increase in a disease that's expensive, incurable, and still shortens lifespan by more than a decade. But the number of new and emerging treatments is surging too, and experts say we're in the most promising era of type 1 diabetes treatments in history, with new medications that slow the disease's progression, advanced insulin delivery systems, inhalable options, and drugs that improve insulin resistance. It's a shift in the management of a chronic lifelong disease for patients who are often diagnosed in childhood. 'These patients are living much longer than they used to with an improved quality of life,' said Kupper A. Wintergerst, MD, a pediatric endocrinologist and executive director of the Wendy Novak Diabetes Institute. Experts attribute the rise in type 1 cases to a few factors. Genetics play a role in who will get type 1 diabetes, increasing a patient's risk by about 40%. And in people with an increased risk, certain environmental factors may serve to nudge them toward getting the disease. For example, infections in early childhood like mumps, rubella, and influenza B as well as childhood obesity and certain environmental factors like antibiotics overuse, vitamin D deficiency, and the hygiene hypothesis — which suggests that kids who aren't exposed to enough microorganisms in childhood may end up with an overactive immune system — may also be playing a role. Additionally, certain chemicals found in foods and drinking water, including PFAS, dioxins, and arsenic, may jolt inflammation in the body. Once these chemicals build up in the bloodstream, it triggers a chronic inflammatory state, which contributes to the immune system mistakenly attacking and destroying its own insulin-producing beta cells in the pancreas. Over time, this lack of beta cells causes the body to stop making insulin, which starts to raise blood sugar. Researchers are responding with new treatment strategies that leverage a slowed progression of the disease while also more accurately monitoring and regulating blood sugars, which all work to extend lifespan. The number of patients living past 65 has tripled in the last four decades. Slowing Progression of the Disease Type 1 diabetes is usually diagnosed in childhood, though it can develop in adulthood, too. A new medication, called teplizumab (Tzield), has been shown to slow the disease's progression, potentially staving off the disease for two or three years. It's now for patients either before they're diagnosed or early after a diagnosis. Once patients have tested positive for two or more type 1 diabetes-related autoantibodies, they're considered eligible for the medicine. They may also have abnormal blood sugar levels but don't yet have other symptoms of type 1 diabetes like excessive thirst, frequent urination, slowed wound healing, and excessive hunger. The medication works by binding to CD3 proteins on the surface of the white blood cell, helping to block the autoimmune attack. The medication must be started a few weeks or months after diagnosis. While it's not good for all patients, it can be helpful especially for children in staving off this life-altering condition for up to three more years of childhood. 'For patients who are early on in their type 1 disease, this medication can help prolong the beta cell function that is remaining and decrease how much insulin a person needs, depending on when it's used in their disease course,' said Bethany L. Gottesman, MD, a pediatric endocrinologist at Phoenix Children's in Phoenix, Arizona. Patients need to visit a facility that offers infusion services over the weekend. These infusion centers are available throughout the country. You can also contact the TZIELD COMPASS Support Program to find a center near you. Beyond slowing the progression of the disease, the next step would be preserving beta cell function indefinitely, which would prevent the disease. Stem cell-derived beta cells are designed to mimic the function of natural beta cells, restoring function to damaged cells before the damage can to type 1 diabetes. A stem cell-derived treatment called zimislecel has shown promising results in early trials, but it is about a decade away from being available to patients, according to experts. Improved Insulin Delivery Systems Science has revolutionized insulin delivery systems, which now do a much better job of mimicking the pancreas — because they measure sugars beneath the skin and between cells and communicate with the insulin pump. A sensor inserted just beneath the skin measures the interstitial fluid that surrounds cells. After that, software built into the device analyzes the glucose data, sending a message to the insulin pump to deliver insulin through a small needle that penetrates the skin. The data gathered from the cells is transmitted wirelessly to a smartphone or directly to an insulin pump. 'As sugar levels rise or fall, the pump can respond by decreasing or increasing the amount of insulin that's delivered through an algorithm,' said Wintergerst. The algorithm is the computer programming process that tells the glucose monitoring system when more insulin is required, all based on data it's collected on blood sugar in the body as well as other potential inputs such as how many carbohydrates a person consumes. The system can provide extra insulin, for example, if it looks like a patient's blood sugar is going to spike. Still, these insulin delivery systems require the user to input the size of a meal or the amount of carbohydrates that a patient is consuming in order to know whether blood sugar is going to go up or go down in the near future, which can make it more difficult for young children. Experts contend that these more optimized systems help patients deal with type 1 diabetic burnout — when people with diabetes become mentally and physically exhausted as a result of all the demands that are put on them in terms of diet and glucose monitoring. This can be a concerning issue especially among children with diabetes who are new to the disease and must tend to their blood sugar for years to come, said Michael Yafi, MD, director of the Pediatric Endocrinology Division at McGovern Medical School at The University of Texas Health Science Center in Houston. When patients are better able to monitor their condition with ease, they're more likely to be able to stay on track with their blood sugar. This way they'll avoid experiencing the organ damage caused by elevated blood sugars, which over time damages the body's blood vessels and nerves, leading to blurred vision, kidney failure, neuropathy, and early death as the body's systems break down. Inhaled Insulin for Both Kids and Adults The inhaled insulin Afrezza provides rapid delivery of insulin to patients after a meal or after exercise to help stabilize blood sugar levels. People with type 1 diabetes will still need insulin injections or an insulin pump to provide a steady, continuous supply of insulin for longer periods of time, but inhaled insulin can provide additional help for people who need a boost of insulin after eating a meal. It can also reduce the risk of hypoglycemia or low blood sugar after exercise because it's faster acting than the injectable version. For example, in patients who eat carbohydrates before exercise to prevent the low blood sugar that impacts their performance, it can keep the body from overcompensating and causing high blood sugar. Afrezza has already been approved for adults and is likely to be approved for children by the end of 2025, giving patients additional options while also easing some of the needle fatigue. Still, it does have its drawbacks, said Gottesman. 'It's not meant to be used if you have lung disease, and some pediatric patients have asthma. This is also true of older patients with type 1 diabetes, who are more likely to have other lung diseases,' she said. Gottesman added that the insulin only comes in set doses, which for the youngest children might not be appropriate. It's typically not as exact as rapid-acting injections. Inhaled versions of insulin provide a convenience factor for patients. It's also discreet for children who are embarrassed by their condition or don't want to inject themselves with needles in public places like at school. Newer versions of inhaled insulin are also in development, perhaps supplying a version of insulin that's liquid rather than powder, which would reduce respiratory irritation. Aerami Therapeutics has a liquid formulation in development, though it's unclear when it will be ready for the public. GLP-1s for Type 1 Diabetes With Insulin Resistance It might seem obvious: In type 1 diabetes, the problem is lack of insulin production. In type 2, it's insulin resistance – the body still makes insulin but can't use it effectively. But that clear-cut distinction doesn't always hold. Many people, including children, with type 1 diabetes develop insulin resistance, too. Despite lacking natural insulin, their bodies can become resistant to the insulin they do receive, for a number of reasons including excess weight, medications, smoking, puberty, and pregnancy. This overlap has led researchers to explore treatments once thought to be reserved only for type 2 diabetes — including GLP-1 medicines like Ozempic and Wegovy — to help patients drop excess weight and stave off or improve insulin resistance, said Alexandra De Lellis, a nurse practitioner at Parkview Endocrinology in Fort Wayne, Indiana. While type 1 diabetes is mostly an autoimmune disease, insulin resistance can be a secondary issue that causes additional complications when the body resists insulin, causing an increase in the amount of insulin required for patients. This happens when the cells don't react efficiently to insulin as a result of excess body weight, a genetic predisposition, or certain medications. 'Insulin resistance plays a large role especially for type 1 patients diagnosed in adulthood but also those who were diagnosed younger,' said De Lellis. It can be frustrating for these patients who feel like their insulin isn't having the impact it should because the body is resisting it. A study published this year in Frontiers in Endocrinology found that GLP-1s were a 'potential adjunctive therapy in [type 1 diabetes] to reduce weight and improve insulin resistance.' Studies have shown that GLP-1s can reduce blood sugars levels by between by 0.21% and 0.96%, while also reducing weight and the amount of insulin that's required of type 1 patients.


Forbes
8 minutes ago
- Forbes
The Science Behind The Fight Over 7-OH
Drug policy is an easy thing to get wrong and a difficult thing to get right. Most drug policy experts agree that total prohibition has failed, but there is little consensus on what might actually work. Drug policy often happens in the ivory towers of government and academia, which can lead to a gap between official rules and street reality—the best example being alcohol remaining legal while less harmful drugs are banned. Why ban a less harmful compound like cannabis when booze is cheap and widely available to adults? And, yet, cannabis is banned at the federal level despite hundreds of human trials showing medical value—a decision rooted more in 'reefer madness' hysteria than science. Now a similar fight may be brewing over a newer compound: 7-hydroxymitragynine (7-OH). 7-OH is a naturally occurring alkaloid found in trace amounts in the kratom plant. Both kratom and 7-OH are mildly psychoactive and sold in smoke shops across much of the U.S. The effects can be either stimulative or sedative, depending on dose and individual metabolism. Why people turn to these products varies greatly but many report doing so for medicinal reasons. In the last couple of years, labs have begun extracting and concentrating 7-OH for sale as a standalone product. Both of these compounds have experienced their share of controversy, which seems to be growing. On July 29th, the Food and Drug Administration (FDA) issued an emergency request to the Drug Enforcement Administration (DEA) to place 7-OH into the most restrictive class in the Controlled Substances Act (CSA)—the same category as heroin. The FDA cited increased risks of dependency given the way 7-OH binds with mu opioid receptors and anecdotal reports of misuse from social media. The FDA has concerns about the potential of 7-OH to be abused and cause harm. 'Today, we're taking action on 7-OH as a critical step in the fight against opioid addiction,' said U.S. Health and Human Services Secretary Robert F. Kennedy, Jr. 'We will protect the health of our nation's youth as we advance our mission to Make America Healthy Again.' The FDA did not request a ban on kratom in its natural form, but because 7-OH is part of kratom's chemistry, any action could have legal spillover effects on kratom itself. Louisiana recently banned both in one move. The DEA can either grant the FDA's emergency scheduling request, removing 7-OH from store shelves immediately, or they may start the normal rulemaking process, which takes 12–18 months. It's an exhaustive process that examines both the scientific data of a compound and citizens' personal experiences with it. There are also public comments and hearings designed to maximize due diligence before the DEA schedules any compound. Congress can also act, but most scheduling decisions are made within the agencies. The DEA may be reluctant to do so this time, given the recent past. The DEA and the FDA already tried to ban the kratom plant in 2016 but withdrew during the process after receiving over 20,000 public comments from advocates, patients, and scientists. Kratom (and 7-OH) may be used by tens of thousands of patients for pain relief and harm reduction. The outcry from these patients was significant enough to cause the FDA to rescind their recommendation to ban both 7-OH and kratom. The FDA Assistant Secretary of Health at the time, Dr. Brett Giroir, concluded more scientific studies were needed before kratom could be credibly banned. He sent a letter to the acting DEA Administrator rescinding the FDA recommendation to place kratom in Schedule 1 of the CSA. While the letter is wonky to read, Girori listed several important scheduling considerations in his letter: 'Further analysis and public input regarding kratom and its chemical components are needed before any scheduling should be undertaken. It is important that we have additional information to justify scheduling, such as: While some of the studies and data that Giroir wanted on kratom and 7-OH may be underway, most of the items he listed are still unknown and no credible data exists to meet the standards cited in his rescinding letter. In the years since, even more people have turned to these compounds for relief, making banning them more complicated than in 2016. One patient I spoke with who uses 7-OH is Zach L., who did not want his last name used for this article. He's struggled with opioid dependency for a long time. 'For the past 10 years, I battled opioid addiction. Fake pills. Xanax. Anything to quiet the storm in my head,' Zach said. 'I overdosed four times. I went to rehab twice.' Then he found 7-OH and things began to improve for him. 'The first time I took it, something changed,' said Zach. 'I didn't feel high. I felt normal. Present. The cravings quieted. The bottomless pit of anxiety and depression eased. For the first time in a decade, I could see a future that didn't end in relapse or worse.' For Zach, 7-OH is a life saver and he believes it's much safer than hard drugs and alcohol. The most recent data available may indicate that kratom and 7-OH are relatively safe compared to legal drugs like alcohol. This data from the 2023 National Poison Data System (NPDS) may be informative to policymakers: Compare this to alcohol: While none of the PhDs I spoke with about 7-OH advocate banning alcohol in this country again, some were troubled by the lack of data the FDA cited in the press release. 'There is not sufficient scientific information or data to meet the criteria for scheduling,' said Dr. Kirsten Smith of John Hopkins University. Dr. Smith works with people with drug-use disorders and takes a real world view of drug policy. She's concerned about what some addicts or chronic pain patients might do if a ban of 7-OH happens. 'People will find something else to use if this is banned and those alternatives may be more harmful than 7-OH.' Dr. Edwin Boyer, Professor of Emergency Medicine at Ohio State University, shared Dr. Smith's concerns about the FDA analysis. 'The problem with the Food and Drug Administration analysis is that it relies heavily on the strength of binding at the mu opioid receptor,' said Dr. Boyer. 'In reality, toxicity is driven by exposure, not strength of binding. The FDA did not consider the degree of exposure following oral administration of 7-hydroxymitragynine in their analysis.' According to a recent article in Reuters, The Marwood Group, a health industry advisory firm, recently completed an independent analysis of data from the FDA, CDC, and other federal agencies that confirms 7-OH's strong real-world safety profile. According to the FDA's Adverse Event Reporting System, there have been no confirmed deaths from 7-OH alone despite more than half a billion estimated doses consumed nationwide. While the Marwood Group may harbor their own biases, one element of the report was striking. Opioid deaths were down significantly across the country in 2023 and 2024. While the availability of Narcan, a drug that reverses overdoses if administered quickly enough, has grown since 2022, it's not at the same rate as the drop in overdose deaths. The report suggested that the increased availability of 7-OH may be contributing to saving lives. The charts, graphs, and patient testimonials in the report are compelling. While the drop in overdose deaths is unquestionably good news, no one really knows why it's happening. While the availability of 7-OH cannot be dismissed as a root cause, like most things regarding 7-OH, its impact on overdose deaths has not yet been measured or studied. In a world where prohibition has failed and legal drugs like alcohol cause massive harm, should a compound with no confirmed fatalities—and potential public health benefits—be banned without more research? Wouldn't science, not panic, lead to better policy?


Forbes
36 minutes ago
- Forbes
Science Or Hysteria? The Fight Over 7-OH
Drug policy is an easy thing to get wrong and a difficult thing to get right. Most drug policy experts agree that total prohibition has failed, but there is little consensus on what might actually work. Drug policy often happens in the ivory towers of government and academia, which can lead to a gap between official rules and street reality—the best example being alcohol remaining legal while less harmful drugs are banned. Why ban a less harmful compound like cannabis when booze is cheap and widely available to adults? And, yet, cannabis is banned at the federal level despite hundreds of human trials showing medical value—a decision rooted more in 'reefer madness' hysteria than science. Now a similar fight may be brewing over a newer compound: 7-hydroxymitragynine (7-OH). 7-OH is a naturally occurring alkaloid found in trace amounts in the kratom plant. Both kratom and 7-OH are mildly psychoactive and sold in smoke shops across much of the U.S. The effects can be either stimulative or sedative, depending on dose and individual metabolism. Why people turn to these products varies greatly but many report doing so for medicinal reasons. In the last couple of years, labs have begun extracting and concentrating 7-OH for sale as a standalone product. Both of these compounds have experienced their share of controversy, which seems to be growing. On July 29th, the Food and Drug Administration (FDA) issued an emergency request to the Drug Enforcement Administration (DEA) to place 7-OH into the most restrictive class in the Controlled Substances Act (CSA)—the same category as heroin. The FDA cited increased risks of dependency given the way 7-OH binds with mu opioid receptors and anecdotal reports of misuse from social media. The FDA has concerns about the potential of 7-OH to be abused and cause harm. 'Today, we're taking action on 7-OH as a critical step in the fight against opioid addiction,' said U.S. Health and Human Services Secretary Robert F. Kennedy, Jr. 'We will protect the health of our nation's youth as we advance our mission to Make America Healthy Again.' The FDA did not request a ban on kratom in its natural form, but because 7-OH is part of kratom's chemistry, any action could have legal spillover effects on kratom itself. Louisiana recently banned both in one move. The DEA can either grant the FDA's emergency scheduling request, removing 7-OH from store shelves immediately, or they may start the normal rulemaking process, which takes 12–18 months. It's an exhaustive process that examines both the scientific data of a compound and citizens' personal experiences with it. There are also public comments and hearings designed to maximize due diligence before the DEA schedules any compound. Congress can also act, but most scheduling decisions are made within the agencies. The DEA may be reluctant to do so this time, given the recent past. The DEA and the FDA already tried to ban the kratom plant in 2016 but withdrew during the process after receiving over 20,000 public comments from advocates, patients, and scientists. Kratom (and 7-OH) may be used by tens of thousands of patients for pain relief and harm reduction. The outcry from these patients was significant enough to cause the FDA to rescind their recommendation to ban both 7-OH and kratom. The FDA Assistant Secretary of Health at the time, Dr. Brett Giroir, concluded more scientific studies were needed before kratom could be credibly banned. He sent a letter to the acting DEA Administrator rescinding the FDA recommendation to place kratom in Schedule 1 of the CSA. While the letter is wonky to read, Girori listed several important scheduling considerations in his letter: 'Further analysis and public input regarding kratom and its chemical components are needed before any scheduling should be undertaken. It is important that we have additional information to justify scheduling, such as: While some of the studies and data that Giroir wanted on kratom and 7-OH may be underway, most of the items he listed are still unknown and no credible data exists to meet the standards cited in his rescinding letter. In the years since, even more people have turned to these compounds for relief, making banning them more complicated than in 2016. One patient I spoke with who uses 7-OH is Zach L., who did not want his last name used for this article. He's struggled with opioid dependency for a long time. 'For the past 10 years, I battled opioid addiction. Fake pills. Xanax. Anything to quiet the storm in my head,' Zach said. 'I overdosed four times. I went to rehab twice.' Then he found 7-OH and things began to improve for him. 'The first time I took it, something changed,' said Zach. 'I didn't feel high. I felt normal. Present. The cravings quieted. The bottomless pit of anxiety and depression eased. For the first time in a decade, I could see a future that didn't end in relapse or worse.' For Zach, 7-OH is a life saver and he believes it's much safer than hard drugs and alcohol. The most recent data available may indicate that kratom and 7-OH are relatively safe compared to legal drugs like alcohol. This data from the 2023 National Poison Data System (NPDS) may be informative to policymakers: Compare this to alcohol: While none of the PhDs I spoke with about 7-OH advocate banning alcohol in this country again, some were troubled by the lack of data the FDA cited in the press release. 'There is not sufficient scientific information or data to meet the criteria for scheduling,' said Dr. Kirsten Smith of John Hopkins University. Dr. Smith works with people with drug-use disorders and takes a real world view of drug policy. She's concerned about what some addicts or chronic pain patients might do if a ban of 7-OH happens. 'People will find something else to use if this is banned and those alternatives may be more harmful than 7-OH.' Dr. Edwin Boyer, Professor of Emergency Medicine at Ohio State University, shared Dr. Smith's concerns about the FDA analysis. 'The problem with the Food and Drug Administration analysis is that it relies heavily on the strength of binding at the mu opioid receptor,' said Dr. Boyer. 'In reality, toxicity is driven by exposure, not strength of binding. The FDA did not consider the degree of exposure following oral administration of 7-hydroxymitragynine in their analysis.' According to a recent article in Reuters, The Marwood Group, a health industry advisory firm, recently completed an independent analysis of data from the FDA, CDC, and other federal agencies that confirms 7-OH's strong real-world safety profile. According to the FDA's Adverse Event Reporting System, there have been no confirmed deaths from 7-OH alone despite more than half a billion estimated doses consumed nationwide. While the Marwood Group may harbor their own biases, one element of the report was striking. Opioid deaths were down significantly across the country in 2023 and 2024. While the availability of Narcan, a drug that reverses overdoses if administered quickly enough, has grown since 2022, it's not at the same rate as the drop in overdose deaths. The report suggested that the increased availability of 7-OH may be contributing to saving lives. The charts, graphs, and patient testimonials in the report are compelling. While the drop in overdose deaths is unquestionably good news, no one really knows why it's happening. While the availability of 7-OH cannot be dismissed as a root cause, like most things regarding 7-OH, its impact on overdose deaths has not yet been measured or studied. In a world where prohibition has failed and legal drugs like alcohol cause massive harm, should a compound with no confirmed fatalities—and potential public health benefits—be banned without more research? Wouldn't science, not panic, lead to better policy?